Ivabradine in heart failure--no paradigm SHIFT…yet (Q42923262)

11 November 2017

title

Ivabradine in heart failure--no paradigm SHIFT…yet (English)

1 reference

11 November 2017

1 reference

1 reference

1

John R Teerlink

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

376

1 reference

11 November 2017

issue

9744

1 reference

11 November 2017

page(s)

847-849

1 reference

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

The role of the funny current in pacemaker activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Fallacies in clinical cardiovascular trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

The Properties of the Pacemaker Current IFin Human Ventricular Myocytes are Modulated by Cardiac Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

Elevated heart rate in cardiovascular diseases: a target for treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961314-1

7 January 2021

10.1016/S0140-6736(10)61314-1

Identifiers

DOI

1 reference

11 November 2017

1 reference